Arterra Bioscience (ARBS) Q3 2025 TU earnings summary

Executive summary

• Revenue as of September 30, 2024, reached approximately €2.8 million, up 7.03% year-over-year.

• Sales of cosmetic raw materials contributed €2.3 million, increasing 7.25% compared to the same period in 2023.

• Service revenues totaled €485 thousand, up 6.04% year-over-year.

• Management expressed confidence in achieving positive full-year results, supported by already acquired orders.

Financial highlights

• Total revenue for the first nine months of 2024 was €2.77 million, compared to €2.59 million in 2023.

• Growth in revenue was slightly lower in Q3 2024 compared to the first half of the year.

Outlook and guidance

• Management remains optimistic for the remainder of the year, citing a strong order backlog.